{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:58:42Z","timestamp":1761487122288},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2004,3,23]],"date-time":"2004-03-23T00:00:00Z","timestamp":1080000000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1038\/sj.bjc.6601724","type":"journal-article","created":{"date-parts":[[2004,3,30]],"date-time":"2004-03-30T17:14:03Z","timestamp":1080666843000},"page":"1329-1333","source":"Crossref","is-referenced-by-count":64,"title":["A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer"],"prefix":"10.1038","volume":"90","author":[{"given":"Y H","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B-Y","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-J","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-T","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,3,23]]},"reference":[{"key":"BF6601724_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/jjco\/hyf057","volume":"32","author":"YJ Bang","year":"2002","unstructured":"Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E, Daglish B, Boudraa Y, Kim WS, Heo DS, Kim NK. (2002) Docetaxel 75\u2009mg\/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer. Jpn J Clin Oncol 32: 248\u2013254","journal-title":"Jpn J Clin Oncol"},{"key":"BF6601724_CR2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/annonc\/mdf089","volume":"13","author":"J Cassidy","year":"2002","unstructured":"Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL. (2002) Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin. Ann Oncol 13: 566\u2013575","journal-title":"Ann Oncol"},{"key":"BF6601724_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3346\/jkms.2002.17.3.348","volume":"17","author":"EK Cho","year":"2002","unstructured":"Cho EK, Lee WK, Lim DY, Bang SM, Park DK, Park YH, Kwon OS, Choi DJ, Shin DB, Lee JH, Lee TH. (2002) Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma. J Korean Med Sci 17: 348\u2013352","journal-title":"J Korean Med Sci"},{"key":"BF6601724_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s101200200025","volume":"5","author":"M Constenla","year":"2002","unstructured":"Constenla M, Garcia-Arroyo R, Lorenzo I, Carrete N, Campos B, Palacios P. (2002) Docetaxel, 5-fluorouracil and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Gastric Cancer 5: 142\u2013147","journal-title":"Gastric Cancer"},{"key":"BF6601724_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF02993858","volume":"13","author":"AI Einzig","year":"1996","unstructured":"Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, Benson AB. (1996) Docetaxel in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG). Med Oncol 13: 87\u201393","journal-title":"Med Oncol"},{"key":"BF6601724_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00001813-200206000-00003","volume":"13","author":"DG Haller","year":"2002","unstructured":"Haller DG, Misset JL (2002) Docetaxel in advanced gastric cancer. Anti-Cancer Drugs 13: 451\u2013460","journal-title":"Anti-Cancer Drugs"},{"key":"BF6601724_CR7","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282\u20132292","journal-title":"J Clin Oncol"},{"key":"BF6601724_CR8","unstructured":"Hong YS, Song SY, Cho JY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS. (2002) A phase II trial of capecitabine (Xeloda) in chemotherapy naive patients with advanced and\/or metastatic gastric cancer. Proc Am Soc Clin Oncol 21, (abstract 623)"},{"key":"BF6601724_CR9","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1002\/1097-0142(20010615)91:12<2288::AID-CNCR1260>3.0.CO;2-8","volume":"15","author":"YT Jeen","year":"2001","unstructured":"Jeen YT, Yoon SY, Shin SW, Kim BS, Mok YJ, Kim CS, Hyun JH, Kim JS, Kim YH. (2001) Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer 15: 2288\u20132293","journal-title":"Cancer"},{"key":"BF6601724_CR10","first-page":"328","volume":"22","author":"YK Kang","year":"2003","unstructured":"Kang YK, Kim TW, Chang HM, Yook JH, Oh ST, Kim BS, Kim WK, Lee JS. (2003) Phase I-II study of docetaxel, capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer. Proc Am Soc Clin Oncol 22: 328 (abstract 1319)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6601724_CR11","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/annonc\/mdf323","volume":"13","author":"TW Kim","year":"2002","unstructured":"Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS, Lee JS. (2002) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13: 1893\u20131898","journal-title":"Ann Oncol"},{"key":"BF6601724_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000069313","volume":"64","author":"W Koizumi","year":"2003","unstructured":"Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y, Taguchi T (2003) Clinical Study Group of Capecitabine. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 64: 232\u2013236","journal-title":"Oncology"},{"key":"BF6601724_CR13","first-page":"321","volume":"22","author":"K Kondo","year":"2003","unstructured":"Kondo K, Chin K, Sakamoto J, Kojima H, Terashima M, Yamamura Y, Tsujinaka T, Hyodo I. (2003) A multicenter phase II trial using 4-week cycles of capecitabine in advanced\/metastatic gastric cancer (AGC). Proc Am Soc Clin Oncol 22: 321 (abstract 1289)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6601724_CR14","first-page":"487","volume":"26","author":"M Mai","year":"1998","unstructured":"Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, Hirabayashi N, Taguchi T, Furue H. (1998) A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B). Jpn J Cancer Chemother 26: 487\u2013496 (in Japanese)","journal-title":"Jpn J Cancer Chemother"},{"key":"BF6601724_CR15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1742-1241.2003.tb10544.x","volume":"57","author":"F McDonald","year":"2003","unstructured":"McDonald F, Miles D (2003) Xeloda and Taxotere: a review of the development of the combination for use in metastatic breast cancer. Int J Clin Pract 57: 530\u2013534","journal-title":"Int J Clin Pract"},{"key":"BF6601724_CR16","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","volume":"34","author":"M Miwa","year":"1998","unstructured":"Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274\u20131281","journal-title":"Eur J Cancer"},{"key":"BF6601724_CR17","unstructured":"National Statistical Office (2001) Annual report on the cause of death statistics in Korea, pp 7\u201315"},{"key":"BF6601724_CR18","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","volume":"20","author":"J O'Shaughnessy","year":"2002","unstructured":"O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812\u20132823","journal-title":"J Clin Oncol"},{"key":"BF6601724_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3322\/canjclin.49.1.33","volume":"49","author":"DM Parkin","year":"1999","unstructured":"Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49: 33\u201364","journal-title":"CA Cancer J Clin"},{"key":"BF6601724_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1054\/bjoc.2000.1160","volume":"83","author":"LC Pronk","year":"2000","unstructured":"Pronk LC, Vasey PA, Sparreboom A, Reigner B, Planting AS, Gordon RJ, Osterwalder B, Verweij J, Twelves C. (2000) A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumors. Br J Cancer 83: 22\u201329","journal-title":"Br J Cancer"},{"key":"BF6601724_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/A:1008328501128","volume":"12","author":"K Ridwelski","year":"2001","unstructured":"Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, Eichelmann K, Lippert H. (2001) Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12: 47\u201351","journal-title":"Ann Oncol"},{"key":"BF6601724_CR22","first-page":"1013","volume":"4","author":"N Sawada","year":"1998","unstructured":"Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013\u20131019","journal-title":"Clin Cancer Res"},{"key":"BF6601724_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s002800050043","volume":"34","author":"J Sch\u00fcller","year":"2000","unstructured":"Sch\u00fcller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B. (2000) Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 34: 291\u2013297","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6601724_CR24","first-page":"1915","volume":"25","author":"T Taguchi","year":"1998","unstructured":"Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, Hirabarashi N. (1998) A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group A). Jpn J Cancer Chemother 25: 1915\u20131924 (in Japanese)","journal-title":"Jpn J Cancer Chemother"},{"key":"BF6601724_CR25","unstructured":"Tebbutt N, Norman A, Cunningham D, Iveson T, Nicholson M, Hickish T, Durrant C, Oates J, Hill M. (2002) Randomised, multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced esophago-gastric cancer; interim analysis. Proc Am Soc Clin Oncol 21, (abstract 523)"},{"key":"BF6601724_CR26","first-page":"63","volume":"26","author":"PC Thuss-Patience","year":"2003","unstructured":"Thuss-Patience PC, Kretzschmar A, Krenn V, Dorken B, Reichardt P (2003) Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion. Onkologie 26: 63\u201365","journal-title":"Onkologie"},{"issue":"Suppl 2","key":"BF6601724_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0959-8049(01)00415-4","volume":"38","author":"C Twelves","year":"2002","unstructured":"Twelves C, on behalf of the Xeloda Colorectal Cancer Group (2002) Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 38(Suppl 2): 15\u201320","journal-title":"Eur J Cancer"},{"issue":"Suppl 5","key":"BF6601724_CR28","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/S1359-6349(03)90086-3","volume":"1","author":"E Van Cutsem","year":"2003","unstructured":"Van Cutsem E, Moiseyenko V, Tjulandin S. (2003) Docetaxel (D), cisplatin (C) 5-fluorouracil (F) compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-na\u00efve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325). Eur J Cancer 1(Suppl 5): S20 (abstract 51A)","journal-title":"Eur J Cancer"},{"key":"BF6601724_CR29","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Van Custem","year":"2001","unstructured":"Van Custem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P. (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097\u20134106","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6601724.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601724","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601724.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T20:22:20Z","timestamp":1705090940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6601724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,23]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["BF6601724"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6601724","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,23]]}}}